Kiromic BioPharma Inc
KRBP
Get informed when a big investor buys or sells
+ FollowMarket Cap$214.93K
Close$
$-0.61
851.9% downside
Current Fair Value
851.9% downsideOvervalued by 851.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $214,932.00 |
|---|---|
| Enterprise Value | $13.65 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.03 |
| Beta | 1.66 |
| Outstanding Shares | 28,518,500 |
Return
| Return on Equity | 214.39% |
|---|---|
| Return on Assets | -315.80% |
| Return on Invested Capital | 197.03% |
Valuation & Multiples
| P/E Ratio | -0.08 |
|---|---|
| PEG | -0.2 |
| Price to Sales | - |
| Price to Book Ratio | -0.08 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.56 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 1.07 |
| Debt to Equity | -1.16 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
November 6, 2025
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Kiromic BioPharma Inc
19 employeesKiromic BioPharma, Inc. is an immuno-oncology biopharmaceutical company focused on discovering, developing, and commercializing novel immuno-oncology applications through its robust product pipeline. The pipeline development is leveraged...